VERACYTE INC (VCYT)
Health Care · Genomic diagnostics / molecular oncology · NASDAQ
Veracyte is a genomic diagnostics company that develops and commercializes molecular tests to guide treatment decisions in cancer and other serious diseases.
What VERACYTE INC does
Veracyte develops and commercializes genomic diagnostic tests that use molecular analysis to classify disease risk and guide clinical management decisions. The company's primary revenue comes from its flagship tests including Decipher Prostate for prostate cancer risk assessment and Afirma for thyroid nodule classification. Veracyte is transitioning its tests toward in vitro diagnostic (IVD) formats on multiple global platforms while expanding its test portfolio through internal development and strategic acquisitions.
Themes: ["cancer diagnostics","genomic profiling","prostate cancer","thyroid cancer","breast cancer","lung cancer","minimal residual disease detection","precision medicine"]
Fundamentals
- Price$59.30 as of 2026-07-09 close
- Market cap$4.5B as of 2026-07-10
- 1-year return+119.0% as of 2026-07-09 close
- P/E50.88 as of 2026-07-10
- Net margin+16.3% as of 2026-07-10
- Gross margin+70.9% as of 2026-07-10
- ROE+6.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+16.9% as of 2026-07-10
- Revenue CAGR (3y)+20.4% SEC XBRL
- Beta1.94 as of 2026-07-10
Key risks (from latest filing)
["Heavy revenue concentration on two flagship tests (Decipher Prostate and Afirma); failure to grow or launch new products could materially impact revenue","Dependence on a few major payers for significant revenue; loss of reimbursement or reduced payer reimbursement rates could substantially decline revenue","Reliance on sole suppliers for critical reagents, equipment, and kit components; supply chain disruptions or inability to transition to alternative suppliers could impair revenue generation"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.